Ultrix Combie (COVID-19 coronavirus and influenza vaccine)

2024: Drug Development

On July 10, 2024, it became known that the first domestic combined vaccine for the prevention of influenza and coronavirus (COVID-19) infection was developed and is being prepared for clinical trials in Russia. A drug called Ultrix Combi, created by the Natsimbio holding of the Rostec state corporation together with the Artgen Biotech group, received permission from the Russian Ministry of Health to conduct clinical trials.

According to Rostec, Ultrix Combi will become the world's second vaccine capable of simultaneously protecting against influenza and COVID-19. The drug contains components for protection against four seasonal strains of influenza viruses developed by Natsimbio, as well as a component providing protection against the SARS-CoV-2 virus, created by companies of the Artgen Biotech group.

source = Natsimbio Telegram channel

Phase I-II clinical trials are planned to be conducted in 370 patients. Their goal will be to study the safety, immunogenicity and tolerability of the new vaccine. To obtain approval for clinical trials, the required amount of preclinical studies was performed in accordance with international requirements.

Natsimbio CEO Andrei Zagorski emphasized the importance of developing:

{{quote 'A combined preventive action drug will answer the challenges facing healthcare related to the control of respiratory viral diseases. Both influenza and covid are capable of causing significant damage to both the economy and public health in a short time.]]

The developers note that the introduction of a combined vaccine in the vaccination calendar can reduce the total costs health care of vaccination against influenza and COVID-19 separately. In addition, this should increase the effectiveness of the vaccine campaign and increase population immunity, which will generally hinder the development of pandemics.^[1]

Notes